We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Aventis Triumphs In Patent Suit Over ALS Drug

Law360 (July 27, 2007, 12:00 AM EDT) -- A Delaware federal court has buried Impax Laboratories Inc.'s efforts to market a generic version of a Sanofi-Aventis U.S. LLC treatment for Lou Gehrig's disease by validating a patent for the Aventis drug Rilutek.

Impax announced Friday that the Delaware federal court has validated the patent on the grounds of anticipation. The court had already thrown out Impax's claims that the patent was acquired by inequitable conduct.

Impax had argued that previous research covered by another Aventis patent, U.S. Patent Number 5,236,940, had anticipated the use...
To view the full article, register now.